Operating Income Summary of SCI Pharmtech, Inc.

SCI Pharmtech, Inc.'s latest annual operating income in 2023 was 160.3 Million TWD , down -7.76% from previous year.
SCI Pharmtech, Inc.'s latest quarterly operating income in 2024 Q2 was 55.07 Million TWD , down -5.33% from previous quarter.
SCI Pharmtech, Inc. reported an annual operating income of 404.29 Million TWD in 2022, up 538.65% from previous year.
SCI Pharmtech, Inc. reported an annual operating income of 63.3 Million TWD in 2021, down -86.52% from previous year.
SCI Pharmtech, Inc. reported a quarterly operating income of 58.17 Million TWD for 2024 Q1, up 933.86% from previous quarter.
SCI Pharmtech, Inc. reported a quarterly operating income of 44.14 Million TWD for 2023 Q3, down -82.86% from previous quarter.

Annual Operating Income Chart of SCI Pharmtech, Inc. (2023 - 2009)

Historical Annual Operating Income of SCI Pharmtech, Inc. (2023 - 2009)

Year	Operating Income	Operating Income Growth
2023	160.3 Million TWD	-7.76%
2022	404.29 Million TWD	538.65%
2021	63.3 Million TWD	-86.52%
2020	469.71 Million TWD	-33.39%
2019	705.2 Million TWD	36.47%
2018	516.74 Million TWD	120.32%
2017	234.54 Million TWD	-54.59%
2016	516.45 Million TWD	17.46%
2015	439.68 Million TWD	48.86%
2014	295.36 Million TWD	43.48%
2013	205.85 Million TWD	-18.26%
2012	251.84 Million TWD	35.35%
2011	186.07 Million TWD	-12.51%
2010	212.68 Million TWD	-0.93%
2009	214.68 Million TWD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	55.07 Million TWD	-5.33%
2024 Q1	58.17 Million TWD	933.86%
2023 Q3	44.14 Million TWD	-82.86%
2023 Q4	-6.97 Million TWD	-115.8%
2023 Q1	78.13 Million TWD	-23.11%
2023 Q2	257.63 Million TWD	229.72%
2023 FY	372.93 Million TWD	-7.76%
2022 Q2	179.7 Million TWD	229.25%
2022 FY	404.29 Million TWD	538.65%
2022 Q1	54.58 Million TWD	295.61%
2022 Q4	101.62 Million TWD	48.59%
2022 Q3	68.39 Million TWD	-61.94%
2021 Q1	57.35 Million TWD	-75.21%
2021 Q3	36.79 Million TWD	581.24%
2021 Q2	5.4 Million TWD	-90.58%
2021 FY	63.3 Million TWD	-86.52%
2021 Q4	-27.9 Million TWD	-175.84%
2020 FY	469.71 Million TWD	-33.39%
2020 Q2	295.2 Million TWD	5.35%
2020 Q3	243.63 Million TWD	-17.47%
2020 Q4	231.36 Million TWD	-5.04%
2020 Q1	280.2 Million TWD	126.27%
2019 Q1	193.76 Million TWD	50.89%
2019 Q4	123.83 Million TWD	-35.29%
2019 FY	705.2 Million TWD	36.47%
2019 Q3	191.37 Million TWD	1.72%
2019 Q2	188.14 Million TWD	-2.9%
2018 Q3	150.62 Million TWD	-4.28%
2018 FY	516.74 Million TWD	120.32%
2018 Q4	128.41 Million TWD	-14.75%
2018 Q2	157.36 Million TWD	95.88%
2018 Q1	80.33 Million TWD	12.21%
2017 Q4	71.59 Million TWD	51.64%
2017 FY	234.54 Million TWD	-54.59%
2017 Q1	65.52 Million TWD	109.11%
2017 Q2	50.21 Million TWD	-23.37%
2017 Q3	47.21 Million TWD	-5.97%
2016 Q1	197.16 Million TWD	168.11%
2016 Q3	125.43 Million TWD	-22.82%
2016 Q4	31.33 Million TWD	-75.02%
2016 FY	516.45 Million TWD	17.46%
2016 Q2	162.52 Million TWD	-17.57%
2015 Q1	115.73 Million TWD	87.13%
2015 Q2	154.8 Million TWD	33.75%
2015 FY	439.68 Million TWD	48.86%
2015 Q3	95.6 Million TWD	-38.24%
2015 Q4	73.53 Million TWD	-23.08%
2014 Q2	77.22 Million TWD	-3.1%
2014 Q4	61.85 Million TWD	-19.26%
2014 FY	295.36 Million TWD	43.48%
2014 Q1	79.69 Million TWD	69.23%
2014 Q3	76.6 Million TWD	-0.8%
2013 FY	205.85 Million TWD	-18.26%
2013 Q3	34.46 Million TWD	-41.38%
2013 Q4	47.09 Million TWD	36.65%
2013 Q2	58.78 Million TWD	-10.28%
2013 Q1	65.52 Million TWD	-9.29%
2012 Q2	42.46 Million TWD	-42.19%
2012 Q1	73.45 Million TWD	47.88%
2012 Q4	72.23 Million TWD	13.68%
2012 Q3	63.54 Million TWD	49.63%
2012 FY	251.84 Million TWD	35.35%
2011 Q3	37.37 Million TWD	-15.75%
2011 Q1	54.65 Million TWD	-14.9%
2011 Q2	44.36 Million TWD	-18.82%
2011 FY	186.07 Million TWD	-12.51%
2011 Q4	49.67 Million TWD	32.9%
2010 FY	212.68 Million TWD	-0.93%
2010 Q2	53.19 Million TWD	9.51%
2010 Q1	48.57 Million TWD	0.0%
2010 Q4	64.22 Million TWD	37.56%
2010 Q3	46.68 Million TWD	-12.23%
2009 FY	214.68 Million TWD	0.0%

Peer Operating Income Comparison of SCI Pharmtech, Inc.

Name	Operating Income	Operating Income Difference
Grape King Bio Ltd	2.49 Billion TWD	93.579%
Standard Chem & Pharm CO., LTD.	1.25 Billion TWD	87.273%
Maywufa Company Ltd.	211.01 Million TWD	24.035%
ScinoPharm Taiwan, Ltd.	314.49 Million TWD	49.029%
Lotus Pharmaceutical Co., Ltd.	4.9 Billion TWD	96.731%
LIWANLI Innovation Co., Ltd.	- TWD	-Infinity%
YungShin Global Holding Corporation	929.61 Million TWD	82.756%
PhytoHealth Corporation	-121.67 Million TWD	231.742%
Formosa Laboratories, Inc.	674.97 Million TWD	76.251%
PharmaEssentia Corporation	- TWD	-Infinity%
Bora Pharmaceuticals Co., LTD.	5.24 Billion TWD	96.946%

Global Stocks Search

SCI Pharmtech, Inc. (4119.TW)

Operating Income Summary of SCI Pharmtech, Inc.

Annual Operating Income Chart of SCI Pharmtech, Inc. (2023 - 2009)

Historical Annual Operating Income of SCI Pharmtech, Inc. (2023 - 2009)

Peer Operating Income Comparison of SCI Pharmtech, Inc.